81946-31-8 Usage
General Description
3-Aminoquinolin-4(1H)-one is an organic compound with the chemical formula C9H8N2O. It is a heterocyclic compound containing a quinoline core structure with an amino group at the 3-position and a carbonyl group at the 4-position. 3-Aminoquinolin-4(1H)-one has potential pharmaceutical applications, as it is being investigated for its antimalarial and anticancer properties. It has been studied as a potential antimalarial agent due to its ability to inhibit the growth of Plasmodium falciparum, the parasite responsible for causing malaria. Additionally, 3-Aminoquinolin-4(1H)-one has also exhibited anticancer activity by inducing cell death in various cancer cell lines. Further research and development of this compound may lead to the discovery of valuable new drugs for the treatment of malaria and cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 81946-31-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,9,4 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 81946-31:
(7*8)+(6*1)+(5*9)+(4*4)+(3*6)+(2*3)+(1*1)=148
148 % 10 = 8
So 81946-31-8 is a valid CAS Registry Number.
81946-31-8Relevant articles and documents
Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator
Hadida, Sabine,Van Goor, Fredrick,Zhou, Jinglan,Arumugam, Vijayalaksmi,McCartney, Jason,Hazlewood, Anna,Decker, Caroline,Negulescu, Paul,Grootenhuis, Peter D. J.
, p. 9776 - 9795 (2015/01/16)
Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.
